Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

The method effectively showed that the two exemestane preparations are bioequivalent.

Entospletinib effectively prevents eye and skin GVHD in mice.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Apremilast showed mixed results for treating severe alopecia areata.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Ixekizumab is safe for long-term use with low rates of major heart-related events.